Skip to main content
. 2014 Mar 25;98(7):926–931. doi: 10.1136/bjophthalmol-2013-304064

Table 1.

Demographics and baseline characteristics (intent-to-treat population)

Bimatoprost/timolol PF (n=278) Bimatoprost/timolol (n=283)
Age, years, mean (range) 63.6 (20–85) 63.5 (23–86)
Gender, n (%)
 Female 159 (57.2) 162 (57.2)
Race, n (%)
 Black 16 (5.8) 14 (4.9)
 Caucasian 221 (79.5) 230 (81.3)
 Asian 6 (2.2) 7 (2.5)
 Hispanic/Latino 35 (12.6) 30 (10.6)
 Other 0 (0.0) 2 (0.7)
Ocular hypotensive medication washout* 223 (80.2) 213 (75.3)
 Brinzolamide 83 (29.9) 80 (28.3)
 Latanoprost 54 (19.4) 59 (20.8)
 Travoprost 42 (15.1) 24 (8.5)
 Timolol 38 (13.7) 31 (11.0)
 Bimatoprost 28 (10.1) 26 (9.2)
 Travoprost/timolol fixed combination 13 (4.7) 16 (5.7)
Iris colour †, n (%)
 Dark 162 (58.3) 171 (60.4)
 Light 116 (41.7) 112 (39.6)
Diagnosis, n (%)
 OHT 55 (19.8) 56 (19.8)
 Glaucoma 220 (79.1) 220 (77.7)
 OHT/Glaucoma‡ 3 (1.1) 7 (2.5)
Mean IOP±SD, mm Hg, average of both eyes
 8:00 24.9±2.1 24.9±2.1
 10:00 24.3±2.5 24.2±2.4
 16:00 23.4±2.9 23.4±2.7
Mean corneal thickness, µm±SD, average of both eyes 552.2±26.4 555.5±27.7

*Patients who required washout of any IOP-lowering medication prior to baseline. The most common medications used at screening (>5% of patients in either group) are listed.

†Iris colour: dark=blue/grey-brown, green-brown, brown, dark-brown and other dark colours; light=blue, blue-grey, grey, green, hazel and other light colours.

‡OHT in one eye and glaucoma in the other eye.

Adapted from Day et al.14

IOP, intraocular pressure; OHT, ocular hypertension; PF, preservative-free.